Tag: aspirin

1. In this pre-specified ancillary study of a randomized control trial, ticagrelor alone after one month was found non-inferior, but not superior, to dual antiplatelet therapy in preventing ischemic events after drug eluting coronary stenting. 2. Ticagrelor did not decrease bleeding risk compared with dual antiplatelet therapy. Evidence Rating Level: 2...
1. The benefit of daily aspirin varied dramatically depending on whether one cardiovascular disease event was equivalent to one or two bleeding events 2. Subgroups that tended to benefit more from aspirin treatment included patients with cardiovascular disease risk factors such as hyperlipidemia, hypertension, diabetes, smokers) and those with lower...
1. The benefit of daily aspirin varied dramatically depending on whether one cardiovascular disease event was equivalent to one or two bleeding events 2. Subgroups that tended to benefit more from aspirin treatment included patients with cardiovascular disease risk factors such as hyperlipidemia, hypertension, diabetes, smokers) and those with lower...
Aspirin (ASA) continues to be used for the primary prevention of cardiovascular disease (CVD) in patients at increased risk, despite evidence consistently demonstrating little benefit in cardiovascular event reduction and increased bleeding risk. Accordingly, the American Heart Association and American College of Cardiology (AHA/ACC) released new guidelines recommending against...
Roxadustat for anemia in patients with kidney disease not receiving dialysis Chronic kidney disease (CKD)-related anemia is associated with significant morbidity, and remains undertreated worldwide. Adequate treatment of CKD-related anemia is associated with reduced transfusion rates and improved clinical outcomes. Roxadustat is a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that...
While dual antiplatelet therapy (DAPT) is the standard of care post-percutaneous coronary intervention (PCI) using drug-eluting stents (DES), the optimal duration of therapy remains controversial. American and European guidelines recommend DAPT for a minimum of 12 months for acute coronary syndrome (ACS), and at least 6 months in stable...
The current standard therapy following percutaneous coronary intervention (PCI) with drug-eluting stents (DES) is dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor, followed by aspirin (ASA) monotherapy. P2Y12 inhibitor monotherapy has recently been suggested as an alternative to DAPT, with studies showing reduced risk of subsequent ischemic...
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial While dual antiplatelet therapy (DAPT) is the standard of care post-percutaneous coronary intervention (PCI) using drug-eluting stents (DES), the optimal duration of...
1. In this systematic review and meta-analysis, use of low-dose aspirin in patients without symptomatic cardiovascular disease was linked with an increased risk of intracranial hemorrhage (ICH). 2. Risk of ICH was greatest amongst those with low body mass, or Asian ethnicity. Evidence Rating Level: 1 (Excellent)       Study Rundown: The use of low-dose...
1. In this systematic review and meta-analysis, use of low-dose aspirin in patients without symptomatic cardiovascular disease was linked with an increased risk of intracranial hemorrhage (ICH). 2. Risk of ICH was greatest amongst those with low body mass, or Asian ethnicity. Evidence Rating Level: 1 (Excellent)       Study Rundown: The use of...